Oral antiplatelet therapies, particularly aspirin or clopidogrel, are effective first-line agents for preventing recurrent vascular events in patients with established vascular disease.
Systematic Review
Does oral antiplatelet therapy prevent recurrent vascular events in patients with cerebrovascular disease, coronary artery disease, and peripheral arterial disease?
Aspirin or clopidogrel are recommended as first-line antiplatelet agents for secondary prevention in most patients with vascular disease, with specific combinations tailored to the clinical presentation.
CONTEXT: Atherothrombosis is a pathophysiologic process that results in clinical ischemic events affecting the cerebral, coronary, and peripheral arterial circulation. Antiplatelet agents, used alone or in combination, are effective in preventing recurrent vascular events among individuals with established vascular disease. OBJECTIVE: To summarize the current state of evidence regarding oral antiplatelet treatment in patients with cerebrovascular disease, coronary artery disease (CAD), and peripheral arterial disease. EVIDENCE ACQUISITION: Using the key terms acute coronary syndrome, atherothrombosis, ischemic stroke, myocardial infarction, MI, peripheral arterial disease, TIA, transient ischemic attack, unstable angina,aspirin,ticlopidine,dipyridamole, and clopidogrel, we searched the MEDLINE database as well as the trial register of the Cochrane Groups to identify studies published from 1960 to August 2004. We manually searched journals and abstract booklets; scrutinized reference lists of trials and review articles; and reviewed meta-analyses, scientific statements, and guidelines from official societies. EVIDENCE SYNTHESIS: Appropriate oral first-line antiplatelet therapy is aspirin for individuals with ST-segment elevation myocardial infarction; aspirin or clopidogrel for those with TIA or stroke, chronic stable angina, or peripheral arterial disease; and aspirin combined with clopidogrel for those with non-ST-segment elevation acute coronary syndrome. Aspirin combined with dipyridamole is a possible alternative for patients who experience a first episode of TIA or stroke in the absence of clinically apparent CAD. Although ticlopidine has been shown to be of benefit in various vascular conditions, its adverse-effect profile has limited its use. CONCLUSIONS: Aspirin, ticlopidine, clopidogrel, aspirin combined with clopidogrel, and aspirin combined with dipyridamole are effective in preventing recurrent vascular events among various subgroups of patients with vascular disease. Current clinical trial evidence favors the use of aspirin or clopidogrel as first-line agents for the majority of patients with vascular disease. Clinical trials evaluating combination antiplatelet therapies will direct future practice.
Huyen Tran (Tue,) conducted a systematic review in Cerebrovascular disease, coronary artery disease, and peripheral arterial disease. Oral antiplatelet therapy (aspirin, clopidogrel, ticlopidine, dipyridamole) was evaluated on Recurrent vascular events. Oral antiplatelet therapies, particularly aspirin or clopidogrel, are effective first-line agents for preventing recurrent vascular events in patients with established vascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: